This site is intended for healthcare professionals

New analysis of Uplizna for neuromyelitis optica spectrum disorder is published in Neurology Neuroimmunology & Neuroinflammation.- Horizon Therapeutics.

Read time: 1 mins
Last updated:8th May 2021
Published:8th May 2021
Horizon Therapeutics plc announced the publication of a new analysis of the pivotal Phase II/III N-MOmentum trial for Uplizna (inebilizumab-cdon), assessing the potential for reduced risk of worsening disability in those living with neuromyelitis optica spectrum disorder (NMOSD).
Condition: Neuromyelitis Optica
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest